Search

Your search keyword '"E. Bilianou"' showing total 26 results

Search Constraints

Start Over You searched for: Author "E. Bilianou" Remove constraint Author: "E. Bilianou"
26 results on '"E. Bilianou"'

Search Results

1. Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH

2. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

3. Lipid profile and body mass index in patients with familial hypercholesterolemia: An analysis from the HELLAS-FH registry

4. Prevalence of non-coronary heart disease in patients with familial hypercholesterolemia: An analysis from the HELLAS-FH

5. Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry

6. Cholesterol levels of high-density lipoprotein (HDL-C), APOB/APOA1 ratio and cardiovascular risk in patients with familial hypercholesterolemia (FH): Data from the HELLAS-FH registry

7. Clinical characteristics of patients with familial hypercholesterolemia: Data from the HELLAS-FH registry

8. Implication of ESC/EAS 2019 dyslipidemia guidelines for PCSK9 inhibition in patients with familial hypercholesterolemia: An analysis from the Hellas-FH registry

9. An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH)

10. l-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study

11. Coexistence of cardiovascular risk factors in patients with familial hypercholesterolemia: Data from the HELLAS-FH registry

12. Latest European guidelines for dyslipidemias in the setting of familial hypercholesterolemia: Data from the hellas-fh registry

13. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

14. Cardiovascular profile and treatment of patients with familial hypercholesterolemia in Greece: Preliminary data from the hellenic registry HELLAS-FH

15. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: A post hoc ATTEMPT analysis

16. Prevalence of Diabetes and Its Association with Atherosclerotic Cardiovascular Disease Risk in Patients with Familial Hypercholesterolemia: An Analysis from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).

17. Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH.

18. Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry.

19. An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).

20. L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study.

21. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

22. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice.

23. Task force on: 'Early markers of atherosclerosis: influence of age and sex'.

24. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.

25. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.

26. The prognostic significance of atrial arrhythmias recorded early after cardioversion for atrial fibrillation.

Catalog

Books, media, physical & digital resources